NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Hiding Enrollment Protocol Failures: SueWallSt

Core Viewpoint - Nektar Therapeutics is facing a securities fraud lawsuit due to allegations of concealing enrollment protocol failures in its clinical trials, which has led to significant investor losses [1][2]. Group 1: Financial Impact - Nektar shares fell by $4.14, or 7.77%, closing at $49.16 on December 16, 2025, following the revelation that four ineligible patients were enrolled in the pivotal REZOLVE-AA study [2]. - The company completed a $115 million underwritten public offering on July 2, 2025, selling 4,893,618 shares at $23.50 per share [6]. Group 2: Timeline of Events - On February 26, 2025, Nektar announced the completion of target enrollment in the Phase 2b REZOLVE-AA trial, emphasizing strict eligibility criteria [6]. - During a Q4/FY 2024 earnings call on March 12, 2025, management highlighted operational features aimed at minimizing clinical operational risk and reiterated the trial's eligibility criteria [6]. - On December 16, 2025, Nektar disclosed that the trial narrowly missed its primary endpoint and that four patients had major eligibility violations [6]. Group 3: Allegations of Misconduct - The lawsuit alleges that Nektar's management consistently cited enrollment criteria as evidence of trial rigor while being aware of violations of those criteria [3]. - Specific allegations include that two patients had unstable alopecia areata diagnosed less than six months before randomization, and two others began treatment before completing the required eight-week washout period [3]. Group 4: Legal Proceedings - Investors who suffered losses between February 26, 2025, and December 15, 2025, may be entitled to recover damages, with the deadline to apply for lead plaintiff status closing on May 5, 2026 [1][4].